Nature Medicine, Published online: 02 September 2025; doi:10.1038/s41591-025-03877-3
A combination of mouse model data and data from a randomized phase 2 trial in patients with breast cancer in remission demonstrates feasibility, safety and a reduction in residual tumor cells following treatment with hydroxychloroquine and/or everolimus.
